Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160614 | 0.94 | ITGA4 (0.44) | UTS2RITGB1ITGA4AADATPKM | |
| SCHEMBL14371684 | 0.89 | ITGB1 (0.37) | UTS2RITGB1ITGA4PTGDR2IRAK4 | |
| SCHEMBL14371589 | 0.88 | ITGA4 (0.43) | ITGB1ITGA4 | |
| SCHEMBL14608580 | 0.88 | ITGA4 (0.37) | ITGB1ITGA4AADATTRPV1PTGDR2 | |
| SCHEMBL5424270 | 0.88 | ALDH1A1 (0.32) | ITGB1ITGA4PTGDR2IRAK4 | |
| SCHEMBL14608620 | 0.87 | ITGA4 (0.38) | ITGB1ITGA4PTGDR2 | |
| SCHEMBL14371579 | 0.87 | ITGA4 (0.45) | ITGB1ITGA4PTGDR2 | |
| SCHEMBL5160840 | 0.87 | ITGB1 (0.52) | ITGB1ITGA4AADATTRPV1 | |
| SCHEMBL14371656 | 0.85 | ITGA4 (0.39) | ITGB1ITGA4PTGDR2 | |
| SCHEMBL14371646 | 0.84 | ITGA4 (0.35) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | UTS2R 3066/4885ITGB1 9/4885ITGA4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.